ATE536376T1 - Humanes bindungsmolekül gegen cd1a - Google Patents
Humanes bindungsmolekül gegen cd1aInfo
- Publication number
- ATE536376T1 ATE536376T1 AT04804973T AT04804973T ATE536376T1 AT E536376 T1 ATE536376 T1 AT E536376T1 AT 04804973 T AT04804973 T AT 04804973T AT 04804973 T AT04804973 T AT 04804973T AT E536376 T1 ATE536376 T1 AT E536376T1
- Authority
- AT
- Austria
- Prior art keywords
- human binding
- binding molecules
- binding molecule
- molecule against
- cd1a
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0351096 | 2003-12-23 | ||
| EP2004052110 | 2004-09-09 | ||
| PCT/EP2004/053639 WO2005063819A2 (en) | 2003-12-23 | 2004-12-21 | Human binding molecule against cd1a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE536376T1 true ATE536376T1 (de) | 2011-12-15 |
Family
ID=34740629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04804973T ATE536376T1 (de) | 2003-12-23 | 2004-12-21 | Humanes bindungsmolekül gegen cd1a |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7968092B2 (de) |
| JP (1) | JP4712724B2 (de) |
| AT (1) | ATE536376T1 (de) |
| ES (1) | ES2378767T3 (de) |
| WO (1) | WO2005063819A2 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003256299A1 (en) * | 2002-07-01 | 2004-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| EP2314629B2 (de) | 2002-07-18 | 2022-11-16 | Merus N.V. | Rekombinante Herstellung von Mischungen aus Aantikörpern |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| PL2248899T3 (pl) | 2003-03-19 | 2015-10-30 | Biogen Ma Inc | Białko wiążące receptor nogo |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
| WO2005000894A2 (en) | 2003-06-25 | 2005-01-06 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| ES2378767T3 (es) | 2003-12-23 | 2012-04-17 | Crucell Holland B.V. | Molécula de unión humana contra CD1a |
| KR101239542B1 (ko) | 2004-06-24 | 2013-03-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 탈수초화를 수반하는 병의 치료 |
| WO2006120230A2 (en) | 2005-05-12 | 2006-11-16 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
| CA2902070A1 (en) | 2005-07-08 | 2007-01-18 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| CL2007002225A1 (es) * | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| EP2059532B1 (de) | 2006-09-07 | 2012-12-26 | Crucell Holland B.V. | Humane bindungsmoleküle, die in der lage sind, das grippevirus h5n1 zu neutralisieren, und anwendungen davon |
| US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| JP2011527572A (ja) | 2008-07-09 | 2011-11-04 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｌｉｎｇｏ抗体または断片を含む組成物 |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| DK2838918T3 (da) | 2012-04-20 | 2019-08-12 | Merus Nv | Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler |
| MX381731B (es) | 2012-05-14 | 2025-03-13 | Biogen Ma Inc | Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras. |
| WO2015042110A1 (en) * | 2013-09-20 | 2015-03-26 | Children's Medical Center Corporation | Treatment of inflammatory skin disease |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) * | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| PE20170676A1 (es) | 2014-09-09 | 2017-05-22 | Janssen Biotech Inc | Terapias de combinacion con anticuerpos anti-cd38 |
| EA202092609A1 (ru) | 2014-12-04 | 2021-10-29 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
| JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用 |
| AU2016215676B2 (en) | 2015-02-02 | 2021-12-02 | Children's Health Care D/B/A Children's Minnesota | Anti-surrogate light chain antibodies |
| CA2986594C (en) | 2015-05-20 | 2025-06-10 | Tufts Medical Center, Inc. | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| AU2017229575A1 (en) * | 2016-03-08 | 2018-09-27 | Janssen Biotech, Inc. | GITR antibodies, methods, and uses |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EA037973B1 (ru) * | 2016-10-12 | 2021-06-18 | Янссен Байотек, Инк. | Антитела к gitr, способы и применение |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | 詹森生物科技公司 | 治疗高危多发性骨髓瘤的方法 |
| WO2020141974A1 (en) * | 2018-12-31 | 2020-07-09 | Merus N.V. | Truncated multivalent multimers |
| KR20230084212A (ko) * | 2020-10-09 | 2023-06-12 | 화이자 인코포레이티드 | CD1a 항체 및 그의 용도 |
| EP4294837A1 (de) | 2021-02-16 | 2023-12-27 | Children's Health Care d/b/a Children's Minnesota | Verfahren zur behandlung von b-all durch verabreichung eines prä-bcr-komplexantagonisten |
| WO2022248839A1 (en) * | 2021-05-26 | 2022-12-01 | Oxford University Innovation Limited | Antibodies |
| TW202430550A (zh) | 2022-10-18 | 2024-08-01 | 日商明治製菓藥業股份有限公司 | Ｔ細胞性腫瘤之治療劑 |
| GB202217923D0 (en) * | 2022-11-29 | 2023-01-11 | Univ Oxford Innovation Ltd | Antibodies |
| WO2025146662A1 (en) | 2024-01-05 | 2025-07-10 | Immunocore Limited | Cd1a-pd-1 bispecific agonist for the treatment of atopic dermatitis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010051156A1 (en) * | 2000-04-28 | 2001-12-13 | Defu Zeng | Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions |
| WO2001082960A1 (en) | 2000-04-28 | 2001-11-08 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of polyclonal b cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking cd1-mediated interactions |
| EP1174440A1 (de) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | Ein selektiv exprimiertes Epitop auf das menschliches CD38 Molekül detektiert von einem "phage display library"-derivierten menschlichen scFv Antikörperfragment |
| WO2002097395A2 (en) * | 2001-05-31 | 2002-12-05 | Chiron Corporation | P-cadherin as a target for anti-cancer therapy |
| EP1465925A4 (de) * | 2001-12-20 | 2006-02-08 | Human Genome Sciences Inc | "antikörper, die sich immunspezifisch an trail?rezeptoren binden" |
| ES2378767T3 (es) | 2003-12-23 | 2012-04-17 | Crucell Holland B.V. | Molécula de unión humana contra CD1a |
-
2004
- 2004-12-21 ES ES04804973T patent/ES2378767T3/es not_active Expired - Lifetime
- 2004-12-21 AT AT04804973T patent/ATE536376T1/de active
- 2004-12-21 WO PCT/EP2004/053639 patent/WO2005063819A2/en not_active Ceased
- 2004-12-21 JP JP2006546178A patent/JP4712724B2/ja not_active Expired - Lifetime
-
2006
- 2006-03-23 US US11/387,997 patent/US7968092B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP4712724B2 (ja) | 2011-06-29 |
| WO2005063819A3 (en) | 2005-10-27 |
| JP2008505605A (ja) | 2008-02-28 |
| WO2005063819A2 (en) | 2005-07-14 |
| US7968092B2 (en) | 2011-06-28 |
| ES2378767T3 (es) | 2012-04-17 |
| US20060257397A1 (en) | 2006-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005063819A3 (en) | Human binding molecule against cd1a | |
| WO2005000894A3 (en) | Binding molecules for the treatment of myeloid cell malignancies | |
| IL225849A0 (en) | Molecules with binding ability that can neutralize rabies virus, and their uses | |
| PH12017502286A1 (en) | Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi) | |
| WO2005012360A3 (en) | Binding molecules against sars-coronavirus and uses thereof | |
| WO2007141274A3 (en) | Human binding molecules having killing activity against staphylococci and uses thereof | |
| CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
| EA200700175A1 (ru) | Композиции и способы лечения воспалительных заболеваний | |
| EA200870594A1 (ru) | Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение | |
| UA101301C2 (ru) | ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ | |
| EA200601776A1 (ru) | Метадоновые композиции местного действия и способы их применения | |
| WO2004065423A3 (de) | Erkennungsmoleküle zur behandlung und detektion von tumoren | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| ATE489957T1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| NO20073574L (no) | Triazolsubstituerte aminobenzofenonforbindelser | |
| ATE448232T1 (de) | Substituierte heterozyklen | |
| BRPI0407662A (pt) | derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas | |
| IL187321A0 (en) | Host cell specific binding molecules capable of neutralizing viruses and uses thereof | |
| WO2005116088A3 (en) | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells | |
| WO2007038459A3 (en) | Carboxyamine compounds and their use in the treatment of hdac dependent diseases | |
| CY1113116T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
| NO20055741D0 (no) | Nye kjemiske forbindelser | |
| WO2006018632A3 (en) | Cell therapy with exo 1 | |
| WO2006029176A3 (en) | Cancer-testis antigens |